Immune Defense Protein Impact On Respiratory Immune Outcomes
A legfontosabb adatok
- Ki végzi
- Quantec Ltd
- Hol
- Los Angeles (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 300 fő, tervezett
- Kezdés
- 2025. dec. 5.
- Tervezett befejezés
- 2026. júl. 31.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Immune Defense Protein 50mg Dose
- IDP 200mg Dose
- Matching Placebo
- A regiszteradat frissítve
- 2026. március 12.
Ki vehet részt
- Életkor
- 60 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Age 60 years and older
- Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season
- Able to read and understand English
- Able to read, understand, and provide informed consent
- Able to use a personal smartphone device and download Chloe by People Science
- Able to receive shipment of the product at an address within the United States
Ki nem vehet részt
- Already in an immunocompromised state, including:; Infectious Causes; HIV/AIDS; Chronic hepatitis B or C (advanced stages); Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related; Leukemia (e.g., AML, ALL, CLL); Lymphoma (e.g., Hodgkin's and Non-Hodgkin's); Multiple Myeloma; Any metastatic cancer receiving chemotherapy; Immunosuppressive Therapy:; Participants on:; Corticosteroids (e.g., ≥20 mg/day of prednisone for ≥2 weeks); Biologics (e.g., TNF inhibitors like infliximab, adalimumab); Calcineurin inhibitors (e.g., tacrolimus, cyclosporine); mTOR inhibitors (e.g., sirolimus); JAK inhibitors (e.g., tofacitinib); Chemotherapy or radiation therapy; Anti-rejection meds post-organ transplant D. Transplant Patients; Solid organ transplant (kidney, liver, heart, lung); Hematopoietic stem cell transplant (HSCT) E. Autoimmune or Inflammatory Diseases (especially when treated with immunosuppressants); Rheumatoid Arthritis; Systemic Lupus Erythematosus (SLE); Psoriasis or Psoriatic Arthritis; Inflammatory Bowel Disease (Crohn's disease, Ulcerative colitis); Multiple Sclerosis (especially on disease-modifying therapies)
- Other Concomitant Conditions and Therapies:; Any investigational therapies or treatments within 30 days prior to enrollment; Known diagnosis of Asthma and/or COPD; Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder; Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes; Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes
- Known hypersensitivity or previous allergic reaction to milk products, Sorbitol and/or tabletting aids
- Any potential participants who:
- Do not have a personal smartphone, internet access, or unwilling to download Chloe
- Use of cannabis-containing products daily
- Use of nicotine-containing products daily
- Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator
Helyszínek itt: Egyesült Államok
- People Science, Inc.Los Angeles, Egyesült ÁllamokContact: Noah Craft, M.D., Ph.DRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.
A vizsgálat 3 csoportja
- Group 1: Study Product 50mg DoseA vizsgált kezelés
50mg of Study Product
Kezelés: Immune Defense Protein 50mg Dose
- Group 2: Study Product 200mg DoseA vizsgált kezelés
200mg of Study Product
Kezelés: IDP 200mg Dose
- Group 3: Matching PlaceboPlacebo, összehasonlításként
Participants will receive Matching Placebo
Kezelés: Matching Placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of IDP® Supplement on Respiratory Immune Health Outcomes During Cold and Flu Season in Older Individuals
- A regiszteradat frissítve
- 2026. március 12.